Literature DB >> 34097178

Fascin promotes the invasion of pituitary adenoma through partial dependence on epithelial-mesenchymal transition.

Hong You1, Jian Xu1, Xiaochun Qin1, Guodong Qian1, Yang Wang1, Fulei Chen1, Xiaoxu Shen1, Dong Zhao1, Qi Liu2.   

Abstract

The aim of the present study was to investigate the role and potential regulatory mechanisms of fascin in the invasion and epithelial-to-mesenchymal transition of pituitary adenoma cells. A total of 30 specimens were assessed in the present study. The expression levels of fascin in the invasive pituitary adenoma group and non-invasive pituitary adenoma group were determined by immunochemistry. Fascin was downregulated via small interfering RNA in mouse pituitary AtT-20 cells. The proliferation, cell cycle and apoptosis of AtT-20 cells were assessed using Cell Counting Kit‑8 and flow cytometry. The invasion of AtT-20 cells was detected using a Transwell assay. Transmission electron microscopy was utilized to observe the ultrastructure of AtT-20 cells. Real-time quantitative PCR, Western blotting and immunofluorescence staining were utilized to detect the expression levels of fascin and EMT markers. In the present study, fascin expression and clinical characteristics were not significantly correlated in pituitary adenoma. The protein expression level of fascin in invasive pituitary adenoma was higher than that in non-invasive pituitary adenoma, as assessed by immunochemistry. Downregulation of fascin resulted in significant decreases in cell viability, proliferation and invasion, arrested the cell cycle at the G1 phase and increased apoptosis. In addition, downregulation of fascin significantly decreased the expression levels of N-cadherin, the mesenchymal cell marker vimentin and the transcription factor Twist but significantly increased the expression levels of the epithelial cell marker E-cadherin. Further experiments revealed that overexpression of E-cadherin resulted in significant decreases in cell viability, proliferation, invasion, and the expression of fascin and transcription factor Twist and also arrested the cell cycle at the G2 phase. The results of the present study suggest that suppressing the expression level of fascin could regulate the invasion, proliferation and apoptosis of pituitary tumour cells and alter the expression level of various EMT markers. The present study identified that fascin effectively promotes the invasion, proliferation and apoptosis of pituitary tumour cells partially via the EMT pathway.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  E-cadherin; Epithelial–mesenchymal transition; Fascin; N-cadherin; Pituitary adenoma; Vimentin

Mesh:

Substances:

Year:  2021        PMID: 34097178     DOI: 10.1007/s10735-021-09995-9

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  39 in total

1.  Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors.

Authors:  Wenya Linda Bi; Noah F Greenwald; Shakti H Ramkissoon; Malak Abedalthagafi; Shannon M Coy; Keith L Ligon; Yu Mei; Laura MacConaill; Matt Ducar; Le Min; Sandro Santagata; Ursula B Kaiser; Rameen Beroukhim; Edward R Laws; Ian F Dunn
Journal:  Endocrinology       Date:  2017-07-01       Impact factor: 4.736

Review 2.  Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance.

Authors:  Hariharan Easwaran; Hsing-Chen Tsai; Stephen B Baylin
Journal:  Mol Cell       Date:  2014-06-05       Impact factor: 17.970

3.  Spinal versus intracranial meningioma: Expression of E-cadherin and Fascin with relation to clinicopathological features.

Authors:  Abd AlRahman Mohammad Foda; Mariya Syed Alam; Nadeem Ikram; Samia Rafi; Khaled Elnaghi
Journal:  Cancer Biomark       Date:  2019       Impact factor: 4.388

Review 4.  Aggressive pituitary tumors.

Authors:  Eleftherios Chatzellis; Krystallenia I Alexandraki; Ioannis I Androulakis; Gregory Kaltsas
Journal:  Neuroendocrinology       Date:  2015-01-05       Impact factor: 4.914

Review 5.  The actin cytoskeleton: a key regulator of apoptosis and ageing?

Authors:  Campbell W Gourlay; Kathryn R Ayscough
Journal:  Nat Rev Mol Cell Biol       Date:  2005-07       Impact factor: 94.444

6.  Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways.

Authors:  Congxin Dai; Bo Zhang; Xiaohai Liu; Kai Guo; Sihai Ma; Feng Cai; Yakun Yang; Yong Yao; Ming Feng; Xinjie Bao; Kan Deng; Yonghui Jiao; Zhenqing Wei; Wei Junji; Bing Xing; Wei Lian; Renzhi Wang
Journal:  Int J Cancer       Date:  2013-06-13       Impact factor: 7.396

7.  Fascin is involved in the chemotherapeutic resistance of breast cancer cells predominantly via the PI3K/Akt pathway.

Authors:  H Ghebeh; S Al-Khaldi; S Olabi; A Al-Dhfyan; F Al-Mohanna; R Barnawi; A Tulbah; T Al-Tweigeri; D Ajarim; M Al-Alwan
Journal:  Br J Cancer       Date:  2014-08-12       Impact factor: 7.640

8.  Long non-coding RNA ZEB1-AS1 regulates miR-200b/FSCN1 signaling and enhances migration and invasion induced by TGF-β1 in bladder cancer cells.

Authors:  Ruxu Gao; Naiwen Zhang; Jianyu Yang; Yuyan Zhu; Zhe Zhang; Jianfeng Wang; Xiaolong Xu; Zeliang Li; Xiankui Liu; Zhenhua Li; Jun Li; Chuize Kong; Jianbin Bi
Journal:  J Exp Clin Cancer Res       Date:  2019-03-01

Review 9.  New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer.

Authors:  Anushka Dongre; Robert A Weinberg
Journal:  Nat Rev Mol Cell Biol       Date:  2019-02       Impact factor: 94.444

10.  Promoter Methylation-Regulated miR-145-5p Inhibits Laryngeal Squamous Cell Carcinoma Progression by Targeting FSCN1.

Authors:  Wei Gao; Chunming Zhang; Wenqi Li; Huizheng Li; Jiangwei Sang; Qinli Zhao; Yunfeng Bo; Hongjie Luo; Xiwang Zheng; Yan Lu; Yong Shi; Dongli Yang; Ruiping Zhang; Zhenyu Li; Jiajia Cui; Yuliang Zhang; Min Niu; Jun Li; Zhongqiang Wu; Huina Guo; Caixia Xiang; Juan Wang; Juan Hou; Lu Zhang; Rick F Thorne; Yongping Cui; Yongyan Wu; Shuxin Wen; Binquan Wang
Journal:  Mol Ther       Date:  2018-09-27       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.